TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03518710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~* Process evaluation:~* Oculomotors: DEM test (5min)~* Visuo-attention: computerized STROOP (15min)~* Visuo-Perceptive: DTVP3 (30min)~* Phonological \& lexical: Exalang (10min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the reading assistance technique
Description: Evaluation of the reading assistance technique (about 30 min) and comprising:~- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)
Study: NCT00948025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollow tube nerve conduit, synthetic or biosynthetic
Description: Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Processed Human Nerve Tissue
Description: Implantation of appropriate length of processed human nerve tissue at time of surgery.
Study: NCT02372409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided laser ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE) MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced (DCE) MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast (DSC) MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast (DSC) MRI
Study: NCT00679003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLCBT
Description: Social learning and cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ES
Description: Education and support (information about nutrition and gastrointestinal system)
Study: NCT03188939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single injection supraclavicular brachial pleuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracluster injection supraclavicular brachial pieuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double injection supraclavicular brachial pleuxus block
Description: the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
Study: NCT00839072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: 100 mg immediate-release tablet, dosing q8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: 300 mg extended-release caplet, single dose
Study: NCT04050293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-538
Description: Patients will receive SPN-538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive Placebo
Study: NCT04251000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Mini
Description: the smallest photomodulation device in the Joovv infrared light product line.
Study: NCT03989804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted follow-up
Description: 2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
Study: NCT02357628

Intervention type: DEVICE
Intervention: Wound treatment with RO-NPT

Intervention type: DEVICE
Intervention: Wound treatment with RO-NPT

Intervention type: DEVICE
Intervention: Wound treatment with RO-NPT

Intervention type: DEVICE
Intervention: Wound Irrigation
Study: NCT03183427

Intervention type: DIAGNOSTIC_TEST
Intervention: MR of the brain
Description: MR of the brain without gadolinium, incl. T2-weighted image

Intervention type: DIAGNOSTIC_TEST
Intervention: MR of the brain
Description: MR of the brain without gadolinium, incl. T2-weighted image
Study: NCT01415830

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-scorpion venom serum Birmex
Description: the dose may be required for the patient according to clinical manifestations and evolution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-scorpion venom serum Alacramyn
Description: The dose may be required fot the patient according to clinical manifestations and evolution
Study: NCT02379416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib + Paclitaxel
Description: The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
Study: NCT04446832

Intervention type: OTHER
Intervention: Vaccine immunogenicity
Description: Evaluation of the vaccine immunogenicity by standard approved serological tests
Study: NCT02624518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: Imaging with PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Imaging with 68Ga-RM2 PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Imaging with 68Ga-RM2 PET/MRI
Study: NCT01084603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: A new l mg oral nicotine product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: A new l mg oral nicotine product
Study: NCT03392779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 175 mg
Description: ZSP1601 tablets administerekd orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 175 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 275 mg
Description: ZSP1601 tablets administered orally once daily in the fasting state
Study: NCT01303289

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-Diet plus Standard
Description: T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity
Description: JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
Study: NCT03392779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 275 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 350 mg
Description: ZSP1601 tablets administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 350mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 50 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT01084603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: A new l mg oral nicotine product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NiQuitinTM Nicotine Lozenge
Description: A marketed 4 mg Nicotine lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette® Nicotine Gum
Description: A marketed 4 mg Nicotine Gum
Study: NCT03202628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT02839356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: 20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20-mL irrigation with physiological saline over the entire papilla
Study: NCT01696383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)
Description: One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
Study: NCT03453502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of breast milk feeding
Description: During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of breast milk feeding
Description: During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
Study: NCT00597584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa or Epoetin beta
Description: Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
Study: NCT02568995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + ketorolac + adrenaline
Description: A combination of drugs injected locally for postoperative pain management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine + ketorolac + adrenaline
Description: A combination of drugs injected locally for postoperative pain management
Study: NCT01392859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine 0.5 Mg/mL Oral Solution
Description: Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine 0.5 Mg/mL Oral Solution
Description: Subjects in two arms, will be enrolled in a classical, randomized, double blind, crossover, placebo controlled trial of Levocetirizine(LCT) with determination of the PD response to LCT as determined by suppression of histamine microvasculature response via HILD.
Study: NCT03736395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Idaho Rural Implementation Model
Description: The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Schools in this condition will receive a four-day training session about SWPBIS.
Study: NCT02823873

Intervention type: DEVICE
Intervention: Pulsewave oscillometric wrist cuff blood pressure monitor
Description: Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.

Intervention type: DEVICE
Intervention: Pulsewave oscillometric wrist cuff blood pressure monitor
Description: Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
Study: NCT05682794

Intervention type: PROCEDURE
Intervention: transanal total mesorectal excision
Description: transanal TME
Study: NCT01996176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention consists of four components, which as described below:~1. Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~2. Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~3. Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~4. Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
Study: NCT01730859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise and ankle taping
Description: Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week.
Study: NCT04525157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02799316

Intervention type: OTHER
Group type: OTHER
Intervention: HBV core antibodies testing. • Real time PCR testing.
Description: * HBV core antibodies testing in HBV surface antigen negative patients.~* Real time PCR testing for those having positive HBc antibodies.
Study: NCT00591422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101-C (Darinaparsin)
Description: Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (\>36 hours between doses) for 3 weeks with 1 week rest.
Study: NCT01735058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
Study: NCT00409578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Description: Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/valsartan 300/320 mg
Description: Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
Study: NCT01993433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT03392779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Study: NCT04291716

Intervention type: DEVICE
Group type: OTHER
Intervention: Motor Seizure Detection Algorithm (mSDA)
Description: A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
Study: NCT01394263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin hydrogel implant
Description: 50 mg histrelin acetate in hyrogel implant
Study: NCT00866840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 100 mg orally twice daily
Study: NCT03362255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different speed of injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different speed of injection